Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer

Trial Profile

Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Mavelertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 13 Mar 2018 Planned End Date changed from 1 Jul 2022 to 12 Jul 2022.
    • 13 Mar 2018 Planned primary completion date changed from 1 Mar 2021 to 28 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top